PhysioMimix Core combines single-organ, multi-organ, and high-throughput configurations in one microphysiological system.
CN Bio has launched PhysioMimix Core, an organ-on-a-chip system that integrates the capabilities of the company’s existing instrument suite into a single microphysiological system platform.
The system delivers validated performance across single-organ, multi-organ, and higher-throughput configurations, supporting high throughput screens of up to 288 samples simultaneously. The benchtop design features tubeless, microfluidic engineering intended to reduce contamination risk and eliminate daily maintenance requirements.
PhysioMimix Core provides recirculating media and adjustable inter/intra-organ flow rates to maintain biomarker levels and enable long-term studies including repeat dosing or chronic disease modeling. The system is configured to yield material recovery for multi-omics analysis.
“PhysioMimix Core directly addresses the gap in the market for a unified [organ-on-a-chip] system that is adaptable across the entire drug discovery and development pipeline,” says Dr Paul Brooks, CEO of CN Bio, in a release. “We work closely with regulators to anticipate the direction of the field, and this launch represents our focus on streamlining adoption and ensuring our customers stay ahead of that curve.”
Platform Designed for Scalability
The PhysioMimix brand builds on more than a decade of organ-on-a-chip expertise and is recognized by the FDA. The technology is used by pharmaceutical companies globally and supported by validated protocols, consumables, and kits.
The system provides an end-to-end solution for recreating human physiology in vitro, optimized for simplicity and functionality. Researchers can adopt, adapt, and scale organ-on-a-chip workflows as experiments evolve within the single platform.
“By combining the strengths of all our existing systems into one intuitive platform, we’ve created a solution that delivers physiological precision with ease-of-use,” says Sung Lee, director of product management at CN Bio, in a release. “With PhysioMimix Core, scientists gain unprecedented control and scalability, enabling them to push boundaries and accelerate breakthroughs across the drug development pipeline.”
Regulatory Environment Supports Adoption
Brooks noted that 2025 has seen legislative changes demonstrating a shift toward new approach methodologies, allowing drug developers flexibility to choose tools for advancing their research while minimizing reliance on animal models.
The organ-on-a-chip technology enables insights into how drugs will perform in patients, potentially reducing risks in clinical trials. The system is designed to be future-proof as the field evolves rapidly.
